Brain shuttle peptides derived from natural proteins.
Brain shuttle peptides are shaking up central nervous system research. These small, protein-inspired sequences are unlocking new ways to move compounds across the blood-brain barrier (BBB)—the main roadblock for brain-targeted research. Most molecules, even well-designed ones, hit a wall at the BBB. Brain shuttle peptides, though, act like VIP passes, ferrying small molecules, proteins, and even antibodies into brain tissue.
Adv Pharmacol
by Nikolić A, Todorovski T
“Brain shuttle peptides derived from natural proteins. Nikolić A(1), Todorovski T(2). Author information: (1)University of Rijeka, Faculty of Biotechnology and Drug Development, Rijeka, Croatia. (2)University of Rijeka, Faculty of Biotechnology and Drug Development, Rijeka, Croatia. Electronic address: toni.todorovski@uniri.hr. Blood-brain barrier (BBB) is the primary physiological barrier that regulates the movement of substances between the systemic circulation and the brain. Its unique structure, based on specialized endothelial cells, allows tight regulation of central nervous system (CNS) homeostasis and at the same time is the main hurdle in the modern medicine to treat neurological conditions. Many promising in vitro drugs become ineffective in vivo due to BBB restrictive permeability. However, in the last two decades, a variety of molecules, mainly peptide-based and named brain shuttle peptides, were able to ferry various payloads (small molecules, proteins, antibodies etc.) into the brain. Therefore, these shuttles could become key future therapeutics to fight various CNS conditions. Brain shuttle peptides are part of a larger family of cell-penetrating peptides (CPPs) that utilize different modes of membrane transport with predominance of adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT). The discovery and development process of new brain shuttle peptides is mainly guided by using rational design and bioinformatics approaches focusing mostly on proteins from natural sources (viruses, amphibians, reptiles and mammals). In the last years, the virus- and mammal-derived brain shuttle peptides have been gaining increased attention due to their superb translocation capacity, low immunogenicity and toxicity, good stability and ease of preparation. Here, we will focus on the most prominent brain shuttle peptides of viral and animal origin with documented BBB crossing capabilities, discussing their mechanisms of translocation and therapeutic applications. Notably, the two brain shuttle peptides that have successfully progressed to clinical trials thus far originate from a viral source (TAT) and a mammalian source (Angiopep-2). Copyright © 2026. Published by Elsevier Inc.”
Researchers have been reverse-engineering these shuttles from natural proteins found in viruses, mammals, amphibians, and reptiles. The goal: design peptides that get in fast, stay stable, and don’t trigger immune alarms. Recent work zeroes in on viral and mammalian origins, which seem to offer the best combo of efficiency and low toxicity. Two names stand out: TAT (from HIV-1) and Angiopep-2 (from mammals). Both have proven their crossing ability in the lab and have already made it into clinical trials.
Why does this matter? If you’re working on CNS research, these brain shuttle peptides could be the gateway for testing new compounds in the brain—something that’s been nearly impossible until now. Key advantages:
High translocation capacity—get more of your payload across the BBB
Low immunogenicity—less immune reaction, more reliable results
Easy to synthesize and modify for different research needs
Compatible with a wide range of payloads, from small molecules to proteins
The pipeline of brain shuttle peptide research keeps growing, driven by rational design and bioinformatics. For a deep dive into related compounds and their mechanisms, check the peptide research index. If you’re looking to source materials for your own experiments, our vendor directory lists reputable suppliers.
Bottom line: brain shuttle peptides are changing the game for anyone studying the brain. Keep an eye on this field—it’s moving fast.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.